Editor

David Chen

Editor · drug development, then telehealth

This index is edited by someone who has worked on both sides of the market it measures — years inside drug development, and a period previously spent helping run a telehealth practice that prescribed GLP-1 medications. That is why the site is built around what a seller actually bills rather than what it advertises: from the inside, the gap between those two numbers is not a mystery.

The editor is not a licensed clinician, and this site gives no medical advice. Every clinical statement here is sourced to FDA prescribing information or to a named paper whose PMID has been verified against the record. Where the label is silent, the page says the label is silent rather than filling the gap.

What this site publishes is arithmetic, not opinion. Every price is read off a seller's own checkout rather than its marketing copy, stored with the date it was checked and a link to where it was read, then restated over a 30.4375-day calendar month from the amount actually charged and the period it covers. The method is written out in full at /how-we-verify and the whole dataset is downloadable, so a reader does not have to take the editor's word for any figure — that is the point.

What this site covers

382 US sellers of compounded tirzepatide, each price read on the seller’s own checkout and restated as a real calendar month. The method is at how we verify, the corrections log at corrections, and the commercial relationships at disclosure.

What this page is not

Nothing on this site is medical advice, and the editor is not a licensed clinician. Clinical statements are sourced to the approved product’s label or to a named paper with its PMID verified against the record — see the medical disclaimer and the editorial policy.